Skip to main content
Top
Published in: Obesity Surgery 7/2011

01-07-2011 | Clinical Research

Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects

Authors: Juan Patricio Valderas, Veronica Irribarra, Lorena Rubio, Camilo Boza, Manuel Escalona, Yessica Liberona, Andrea Matamala, Alberto Maiz

Published in: Obesity Surgery | Issue 7/2011

Login to get access

Abstract

Background

The effects of medical and surgical treatments for obesity on glucose metabolism and glucagon-like peptide 1 (GLP-1) levels independent of weight loss remain unclear. This study aims to assess plasma glucose levels, insulin sensitivity and secretion, and GLP-1 levels before and after sleeve gastrectomy (SG) or medical treatment (MED) for obesity.

Methods

This study is a prospective, controlled, non-randomised study. Two groups of non-diabetic obese patients with similar BMIs, including a SG group (BMI, 35.5 ± 0.9 kg/m2; n = 6) and a MED group (BMI, 37.7 ± 1.9 kg/m2; n = 6) and a group of lean subjects (BMI, 21.7 ± 0.7 kg/m2; n = 8).

Results

Plasma glucose, insulin, and total GLP-1 levels at fasting and after the intake of a standard liquid meal at baseline and at 2 months post-intervention. At baseline, total GLP-1 levels were similar, but obese patients had lower insulin sensitivity and higher insulin secretion than lean subjects. At 2 months post-intervention, SG and MED patients achieved similar weight loss (14.4 ± 0.8%, 15.3 ± 0.9%, respectively). Insulin sensitivity increased in SG and MED patients; however, postprandial insulin secretion decreased after MED, but not after SG. The incremental area under the curve of GLP-1 increased after SG (P = 0.04), but not after MED.

Conclusions

Weight loss by medical or surgical treatment improved insulin sensitivity. However, only MED corrected the hyperinsulinemic postprandial state associated to obesity. Postprandial GLP-1 levels increased significantly after SG without duodenal exclusion, which may explain why insulin secretion did not decrease following this surgery.
Literature
1.
go back to reference Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.CrossRef Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.CrossRef
2.
3.
go back to reference DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia. 2010;53:1270–87.PubMedCrossRef DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia. 2010;53:1270–87.PubMedCrossRef
4.
go back to reference Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317–35.PubMedCrossRef Avenell A, Brown TJ, McGee MA, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317–35.PubMedCrossRef
5.
go back to reference Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMedCrossRef
6.
go back to reference Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef
7.
go back to reference Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145–54.PubMedCrossRef Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145–54.PubMedCrossRef
8.
go back to reference Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for sleeve gastrectomy, March 19–21, 2009. Surg Obes Relat Dis. 2009;5:476–85.PubMedCrossRef Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for sleeve gastrectomy, March 19–21, 2009. Surg Obes Relat Dis. 2009;5:476–85.PubMedCrossRef
9.
go back to reference Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–41.PubMedCrossRef Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–41.PubMedCrossRef
11.
go back to reference Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009;23:425–32.PubMedCrossRef Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009;23:425–32.PubMedCrossRef
13.
go back to reference Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19:217–29.PubMedCrossRef
14.
go back to reference Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069–75.PubMedCrossRef Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069–75.PubMedCrossRef
15.
go back to reference van Delft J, Uttenthal O, Koch C, et al. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism. 1999;48:41–6.PubMedCrossRef van Delft J, Uttenthal O, Koch C, et al. Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. Metabolism. 1999;48:41–6.PubMedCrossRef
16.
go back to reference Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
17.
go back to reference Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care. 1999;22:1462–70.CrossRef Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care. 1999;22:1462–70.CrossRef
18.
go back to reference Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diab Care. 2000;23:295–301.CrossRef Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diab Care. 2000;23:295–301.CrossRef
19.
go back to reference Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618–21.PubMedCrossRef Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618–21.PubMedCrossRef
20.
go back to reference Maki KC, McKenney JM, Farmer MV, et al. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutr J. 2009;28:1–10. Maki KC, McKenney JM, Farmer MV, et al. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutr J. 2009;28:1–10.
21.
go back to reference Navaneethan SD, Kelly KR, Sabbagh F, et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–15.PubMedCrossRef Navaneethan SD, Kelly KR, Sabbagh F, et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–15.PubMedCrossRef
22.
go back to reference Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53:S26–33.PubMedCrossRef Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes. 2004;53:S26–33.PubMedCrossRef
23.
go back to reference Pereira JA, Claro BM, Pareja JC, et al. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes Relat Metab Disord. 2003;27:463–8.PubMedCrossRef Pereira JA, Claro BM, Pareja JC, et al. Restored insulin inhibition on insulin secretion in nondiabetic severely obese patients after weight loss induced by bariatric surgery. Int J Obes Relat Metab Disord. 2003;27:463–8.PubMedCrossRef
24.
go back to reference Jimenez J, Zuniga-Guajardo S, Zinman B, et al. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab. 1987;64:661–8.PubMedCrossRef Jimenez J, Zuniga-Guajardo S, Zinman B, et al. Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. J Clin Endocrinol Metab. 1987;64:661–8.PubMedCrossRef
25.
go back to reference Letiexhe MR, Scheen AJ, et al. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord. 1994;18:295–300.PubMed Letiexhe MR, Scheen AJ, et al. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes Relat Metab Disord. 1994;18:295–300.PubMed
26.
go back to reference Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.PubMedCrossRef Morínigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.PubMedCrossRef
27.
go back to reference Camastra S, Manco M, Mari A, et al. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes. 2005;54:2382–9.PubMedCrossRef Camastra S, Manco M, Mari A, et al. Beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes. 2005;54:2382–9.PubMedCrossRef
28.
go back to reference Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16.CrossRef Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16.CrossRef
29.
go back to reference Horowitz M, Cook DJ, Collins PJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655–7.PubMedCrossRef Horowitz M, Cook DJ, Collins PJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg. 1982;69:655–7.PubMedCrossRef
30.
go back to reference Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57–62.PubMedCrossRef Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57–62.PubMedCrossRef
31.
go back to reference Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.PubMed Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–8.PubMed
32.
go back to reference Langer FB, Reza Hoda MA, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024–9.PubMedCrossRef Langer FB, Reza Hoda MA, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024–9.PubMedCrossRef
33.
go back to reference Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–6.PubMedCrossRef Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86:5083–6.PubMedCrossRef
34.
go back to reference Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedCrossRef Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedCrossRef
35.
go back to reference Guldstrand M, Ahrén B, Näslund E, et al. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Diabetes Obes Metab. 2009;1:1027–33.CrossRef Guldstrand M, Ahrén B, Näslund E, et al. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Diabetes Obes Metab. 2009;1:1027–33.CrossRef
36.
go back to reference Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54.PubMedCrossRef Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54.PubMedCrossRef
37.
go back to reference Christensen M, Knop FK, Vilsbøll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept. 2010;163:96–101.PubMedCrossRef Christensen M, Knop FK, Vilsbøll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept. 2010;163:96–101.PubMedCrossRef
38.
go back to reference Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regul Pept. 2002;110:39–45.PubMedCrossRef Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regul Pept. 2002;110:39–45.PubMedCrossRef
39.
go back to reference Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165–74.PubMed Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987;47:165–74.PubMed
Metadata
Title
Effects of Sleeve Gastrectomy and Medical Treatment for Obesity on Glucagon-like Peptide 1 Levels and Glucose Homeostasis in Non-diabetic Subjects
Authors
Juan Patricio Valderas
Veronica Irribarra
Lorena Rubio
Camilo Boza
Manuel Escalona
Yessica Liberona
Andrea Matamala
Alberto Maiz
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 7/2011
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0375-4

Other articles of this Issue 7/2011

Obesity Surgery 7/2011 Go to the issue

Letter to the Editor

Differences in Deficiencies